Shots:
- The companies shared the additional efficacy and safety data of the ACTT-2 study demonstrating baricitinib + remdesivir reduced time to recovery and improved clinical outcomes for patients with COVID-19 infection compared with remdesivir as monothx
- The biggest benefits were observed in patients requiring supplemental oxygen (grade 5 on the eight-point ordinal scale) and those who required high-flow oxygen/non-invasive ventilation (grade 6) at baseline
- Additionally, Eli Lilly is in talks with the US FDA for EUA of baricitinib (JAK1/JAK2 inhibitor licensed to Lilly from Incyte) to treat hospitalized patients with COVID-19
Click here to read full press release/ article | Ref: Eli Lilly | Image: Strateos Blog
Related News: Eli Lilly and Incyte’s Olumiant + Gilead’s Veklury Reduce Time to Recovery in Hospitalized Patients with COVID-19
The post Lilly and Incyte’s Olumiant (baricitinib) Reports Additional Data Demonstrating Reduction in COVID-19 Recovery Time first appeared on PharmaShots.
